Scholars Central

Research articlePublished 2013

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer

Authors: Lian Lam, Brian J. Czerniecki, Elizabeth Fitzpatrick, Shuwen Xu, Lynn Schuchter, Xiaowei Xu, Hongtao Zhang

Journal of Molecular Biomarkers & Diagnosis

Volume 4 · Issue 3 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Over-expression of the HER2/neu receptor occurs in 20 to 30 percent of breast tumors and is linked to poorer prognosis. The HER2/neu expression status determines whether or not patient will receive trastuzumab- based treatment. In clinical practice, over-expression of HER2/neu is routinely identified using Immunohistochemistry (IHC) or Fluorescence in Situ Hybridization (FISH), both of which are invasive approaches requiring tissue samples. Serum assays for the Extra Cellular Domain of HER2/neu receptor (HER2 ECD) have been reported but the use is very limited due to serum interference factors (e.g. human anti-animal immunoglobulin antibodies) that lead to false test results and inconsistency with tissue Her2 status. We have developed an ELISA based approach using an MBB buffer to eliminate false results and to obtain more accurate assessment of HER2 ECD levels. Using this refined assay we retroactively measured HER2/neu levels from breast cancer patients and controls. Abnormal HER2 ECD levels were detected in about 32% of invasive breast cancer patients but not in controls or patients with benign diseases. In addition, we also showed that patients with elevated serum HER2 levels appeared to have worse survival regardless of treatments. In a small group of 12 Ductal Carcinoma in situ (DCIS) patients who received HER2/neu peptide vaccination and surgery, only one patient showed constantly rising HER2 levels after treatment and this patient had recurrence of HER2 positive tumor within 5 years. Our studies indicate that once the serum interference issue is resolved, serum HER2 ECD can have potential clinical utility to supplement the tissue based tests.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Biomarkers & Diagnosis
  • SubjectGenetics & Molecular Biology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Lian Lam”
  • BylineArticles whose byline prints “Brian J. Czerniecki”
  • BylineArticles whose byline prints “Elizabeth Fitzpatrick”
  • BylineArticles whose byline prints “Shuwen Xu”
  • BylineArticles whose byline prints “Lynn Schuchter”
  • BylineArticles whose byline prints “Xiaowei Xu”
  • BylineArticles whose byline prints “Hongtao Zhang”